Involved-lesion radiation therapy after chemotherapy in limited-stage head-and-neck diffuse large B cell lymphoma

International Journal of Radiation Oncology Biology Physics

Volumn 78, Issue 2, 2010, Pages 507-512

  Yu, Jeong Il ^a   Nam, Heerim ^a   Ahn, Yong Chan ^a   Kim, Won Seog ^a   Park, Keunchil ^a   Kim, Seok Jin ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Diffuse large B cell lymphoma; Head and neck; Radiation therapy

Indexed keywords

CHEMOTHERAPY; MULTIVARIANT ANALYSIS; ONCOLOGY; RADIOTHERAPY; STATISTICAL PROCESS CONTROL;

DIFFUSE LARGE B-CELL LYMPHOMA; DISTANT METASTASIS; DOXORUBICIN; FIELD FAILURE; FOUR CYCLES; GROSS LESIONS; HEAD AND NECK; IN-FIELD; LACTATE DEHYDROGENASE; MUCOSITIS; MULTI VARIATE ANALYSIS; OVERALL SURVIVAL; RADIATION THERAPY; RADIATION TOXICITY; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOMES;

RADIATION;

CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; DISTANT METASTASIS; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIATION DOSE; TREATMENT FAILURE; TREATMENT OUTCOME; XEROSTOMIA; AGE; BLOOD; DISEASE FREE SURVIVAL; HEAD AND NECK NEOPLASMS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; RECURRENT DISEASE; TUMOR VOLUME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; L-LACTATE DEHYDROGENASE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDNISONE; RADIOTHERAPY DOSAGE; RECURRENCE; TREATMENT OUTCOME; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE; YOUNG ADULT;

EID: 77956529144     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.07.1706     Document Type: Article

References (27)

1. H.S. Kaplan Hodgkin's disease: Unfolding concepts concerning its nature, management and prognosis Cancer 45 1980 2439 2474
2. Z. Fuks, and H.S. Kaplan Recurrence rates following radiation therapy of nodular and diffuse malignant lymphomas Radiology 108 1973 675 684
3. J.J. Nickson Hodgkin's disease clinical trial Cancer Res 26 1966 1279 1283
4. J. Yahalom, and P. Mauch The involved field is back: Issues in delineating the radiation field in Hodgkin's disease Ann Oncol 13 Suppl. 1 2002 79 83
5. T. Girinsky, R. van der Maazen, and L. Specht Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines Radiother Oncol 79 2006 270 277
6. B.A. Campbell, N. Voss, and T. Pickles Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: A question of field size J Clin Oncol 26 2008 5170 5174
7. J.D. Cox, J. Stetz, and T.F. Pajak Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) Int J Radiat Oncol Biol Phys 31 1995 1341 1346
8. B.D. Cheson, B. Pfistner, and M.E. Juweid Revised response criteria for malignant lymphoma J Clin Oncol 25 2007 579 586
9. T.P. Miller, S. Dahlberg, and J.R. Cassady Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma N Engl J Med 339 1998 21 26
10. F. Reyes, E. Lepage, and G. Ganem ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma N Engl J Med 352 2005 1197 1205
11. A.K. Ng, and P.M. Mauch Role of radiation therapy in localized aggressive lymphoma J Clin Oncol 25 2007 757 759
12. T.N. Shenkier, N. Voss, and R. Fairey Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: An 18-year experience from the British Columbia Cancer Agency J Clin Oncol 20 2002 197 204
13. S.J. Horning, E. Weller, and K. Kim Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484 J Clin Oncol 22 2004 3032 3038
14. B. Coiffier, E. Lepage, and J. Briere CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346 2002 235 242
15. M. Pfreundschuh, L. Trumper, and A. Osterborg CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group Lancet Oncol 7 2006 379 391
16. T.P. Miller The limits of limited stage lymphoma J Clin Oncol 22 2004 2982 2984
17. R.M. Nathu, N.P. Mendenhall, and N.M. Almasri Non-Hodgkin's lymphoma of the head and neck: A 30-year experience at the University of Florida Head Neck 21 1999 247 254
18. R.W. Tsang, M.K. Gospodarowicz, and B. O'Sullivan Staging and management of localized non-Hodgkin's lymphomas: Variations among experts in radiation oncology Int J Radiat Oncol Biol Phys 52 2002 643 651
19. A. Urquhart, and R. Berg Hodgkin's and non-Hodgkin's lymphoma of the head and neck Laryngoscope 111 2001 1565 1569
20. M.G. Chen, L.R. Prosnitz, and A. Gonzalez-Serva Results of radiotherapy in control of stage I and II non-Hodgkin's lymphoma Cancer 43 1979 1245 1254
21. B. Vaughan Hudson, G. Vaughan Hudson, and K.A. MacLennan Clinical stage 1 non-Hodgkin's lymphoma: Long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy Br J Cancer 69 1994 1088 1093
22. R. Elstrom, L. Guan, and G. Baker Utility of FDG-PET scanning in lymphoma by WHO classification Blood 101 2003 3875 3876
23. K. Isohashi, M. Tatsumi, and I. Higuchi (18)F-FDG-PET in patients with malignant lymphoma having long-term follow-up: Staging and restaging, and evaluation of treatment response and recurrence Ann Nucl Med 22 2008 795 802
24. J.B. Epstein, M. Robertson, and S. Emerton Quality of life and oral function in patients treated with radiation therapy for head and neck cancer Head Neck 23 2001 389 398
25. A.D. Krol, H.W. Berenschot, and D. Doekharan Cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy and radiotherapy for stage I intermediate or high grade non-Hodgkin's lymphomas: Results of a strategy that adapts radiotherapy dose to the response after chemotherapy Radiother Oncol 58 2001 251 255
26. W.S. Velasquez, L.M. Fuller, and S. Jagannath Stages I and II diffuse large cell lymphomas: Prognostic factors and long-term results with CHOP-bleo and radiotherapy Blood 77 1991 942 947
27. R.B. Wilder, S.L. Tucker, and C.S. Ha Dose-response analysis for radiotherapy delivered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy Int J Radiat Oncol Biol Phys 49 2001 17 22